Identification of allele-specific RNAi effectors targeting genetic forms of parkinson's disease

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Sibley, Christopher R ^a,b   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; RNA POLYMERASE II; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; HEMIZYGOSITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; PARKINSON DISEASE; PLASMID; PROTEIN DEGRADATION; RNA INTERFERENCE; SEQUENCE ALIGNMENT; ALLELE; CELL LINE; CELL SURVIVAL; GENETICS; MUTATION; PHYSIOLOGY;

ALLELES; ALPHA-SYNUCLEIN; CELL LINE; CELL SURVIVAL; HUMANS; MICROSCOPY, FLUORESCENCE; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING;

EID: 80054843678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026194     Document Type: Article

References (46)

1. Lesage S, Brice A, (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18: R48-59.
2. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
3. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
4. Erson AE, Petty EM, (2008) MicroRNAs in development and disease. Clin Genet 74: 296-306.
5. Kubodera T, Yokota T, Ishikawa K, Mizusawa H, (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15: 298-302.
6. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100: 7195-7200.
7. Miller VM, Gouvion CM, Davidson BL, Paulson HL, (2004) Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32: 661-668.
8. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: e140.
9. Ding H, Schwarz DS, Keene A, Affar el B, Fenton L, et al. (2003) Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2: 209-217.
10. Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, et al. (2009) Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS ONE 4: e7232.
11. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake CH, et al. (2008) Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128: 594-605.
12. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, et al. (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198: 382-390.
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehjia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
14. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
15. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
16. Giasson BI, Van Deerlin VM, (2008) Mutations in LRRK2 as a cause of Parkinson's disease. Neurosignals 16: 99-105.
17. Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H, (2008) Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS ONE 3: e2248.
18. Pandey N, Schmidt RE, Galvin JE, (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 197: 515-520.
19. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
20. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
21. Haley B, Zamore PD, (2004) Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol 11: 599-606.
22. Doench JG, Sharp PA, (2004) Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511.
23. Holen T, Moe SE, Sorbo JG, Meza TJ, Ottersen OP, et al. (2005) Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo. Nucleic Acids Res 33: 4704-4710.
24. Yue Z, (2009) LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. FEBS J 276: 6445-6454.
25. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97: 571-576.
26. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, et al. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322: 1089-1102.
27. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D, (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
28. Gorbatyuk OS, Li S, Gorbatyuk M, Lewin AS, Sullivan LF, et al. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18: 1450-1457.
29. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
30. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM, (2000) Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97: 279-284.
31. Nonaka T, Hasegawa M, (2009) A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry 48: 8014-8022.
32. Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, et al. (2001) Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 77: 1181-1184.
33. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, et al. (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 24: 245-258.
34. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
35. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107: 9879-9884.
36. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005 Apr; 76 (4): 672-80.
37. Wang JJ, Li QS, Li Y, Zheng YR, (2011) Discrimination of Parkinson-associated LRRK2 alleles by introduction of a single nucleotide mismatch into siRNA. Neurosci Lett (2011) doi:10.1016/j.neulet.2011.04.064.
38. Shao Y, Chan CY, Maliyekkel A, Lawrence CE, Roninson IB, et al. (2007) Effect of target secondary structure on RNAi efficiency. RNA 13: 1631-1640.
39. Zhou H, Zeng X, (2009) Energy profile and secondary structure impact shRNA efficacy. BMC Genomics 10 (Suppl 1): S9.
40. Song J-J, Liu J, Tolia NH, Schneiderman J, Smith SK, et al. (2003) The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol 10: 1026-1032.
41. Heale BSE, Soifer HS, Bowers C, Rossi JJ, (2005) siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 33: e30.
42. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41: 706-716.
43. Sibley CR, Seow Y, Wood MJA, (2010) Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18: 466-476.
44. Varani G, McClain WH, (2000) The G x U wobble base pair. A fundamental building block of RNA structure crucial to RNA function in diverse biological systems. EMBO Rep 1: 18-23.
45. Strazewski P, Biala E, Gabriel K, McClain WH, (1999) The relationship of thermodynamic stability at a G x U recognition site to tRNA aminoacylation specificity. RNA 5: 1490-1494.
46. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z, (2005) A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 33: 1671-1677.